23 vipph

Industrial Automation and Control Systems Market Growth Projections to 2031 Honeywell International, Kawasaki Heavy Industries, Mitsubishi Electric Corporation, OMRON Corporation, Rockwell Automation, Schneider ElectricNoneA museum curator hiked into a forest in Poland with a metal detector to search for some artifacts from the World Wars. Instead, he stumbled upon a 3,000-year-old weapon. Krzysztof Mindur planned to explore the forest in Zarszyn in hopes of finding items from World War I or II to add to his museum, the Museum of Military and Technology in Wola Sękowa, he told McClatchy News on Dec. 5. He founded the museum to combine his work as a professional soldier and his passion for researching military history. Mindur and other history enthusiasts tracked down a former battlefield in the Zarszyn forest after talking to those who remembered the fighting. Equipped with metal detectors, the group set out to search the area for the first time in late October. To his surprise, Mindur unearthed four fragments of a sword from the Bronze Age , he wrote in a post on his museum’s Facebook account. Photos show the ancient blue-green sword. The weapon dated back over 3,000 years and was a unique, priceless find, the Subcarpathian Voivodeship Conservator of Monuments in Przemyśl said in a Dec. 3 Facebook post. The ancient sword measured about 15 inches in length, but its point was missing. Its handle had a geometric design carved into it, photos show. The 3,000-year-old sword was sent to the Historical Museum in Sanok for further analysis, TVP3, a Polish news outlet, reported. The museum’s curator, Piotr Kotowicz, identified it as a raga type sword, a style typically found in Slovakia or Hungary, and a first-of-its-kind find for Poland. Officials with the Regional Directorate of State Forests in Krosno described the ancient sword as extraordinary in a Facebook post. Mindur said he never dreamed of finding such a historically valuable artifact. He plans to continue searching former WWII battlefields next year. Zarszyn is a village in southeastern Poland, a roughly 240-mile drive southeast from Warsaw and near the border with Slovakia and Ukraine. Google Translate was used to translate Facebook posts from the Museum of Military and Technology in Wola Sękowa, the Subcarpathian Voivodeship Conservator of Monuments in Przemyśl and the Regional Directorate of State Forests in Krosno, article from TVP3 and comments from Krzysztof Mindur.

HALIFAX — A Nova Scotia charity is serving at least 600 free traditional dinners over Christmas Eve and Christmas Day to spread a little bit of holiday cheer. The Souls Harbour Rescue Mission is offering a sit-down turkey dinner with all the fixings for people who need "food or friends" at mission locations across the province. It's the first time the group is serving the meals over the holidays since it started providing community service in 2010. Michelle Porter, the CEO, says the charity has been raising funds for Christmas festivities since November and estimates the cost for events during the holiday season is around $1 million. Meals will differ slightly at mission locations across the province, but Porter says all plates will have turkey, potatoes, cranberry, gravy and some vegetables. People who attend will also get a Christmas stocking that includes a mini hygiene set and a few treats like chocolate, gloves and socks. About 400 people will eat today in Lower Sackville, Bridgewater, Truro and Sydney Mines, while Porter estimates 200 people will share a meal together in Halifax on Christmas Day. This report by The Canadian Press was first published Dec. 24, 2024. The Canadian PressHow to Watch Top 25 College Basketball Games – Sunday, November 24

REDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the closing of its underwritten public offering of 16,576,088 shares of its common stock at a public offering price of $46.00 per share, before underwriting discounts and commissions, and, in lieu of shares of common stock, to certain investors, pre-funded warrants to purchase 2,173,917 shares of common stock at a public offering price of $45.9999, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant. The shares of common stock issued and sold in the offering include 2,445,652 shares issued upon exercise in full by the underwriters of their option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Revolution Medicines, were $862.5 million. All shares and pre-funded warrants in the offering were offered by Revolution Medicines. J.P. Morgan, TD Cowen, Goldman Sachs & Co. LLC and Guggenheim Securities acted as joint book-running managers for the offering. UBS Investment Bank acted as lead manager. A shelf registration statement relating to these securities was filed with the U.S. Securities and Exchange Commission (SEC) on March 4, 2024, and automatically became effective upon filing. This offering was made solely by means of a prospectus. A copy of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained for free by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, a copy of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained by contacting: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846 or by email at TD.ECM_Prospectus@tdsecurities.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at prospectus-ny@ny.email.gs.com; and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017, by telephone at (212) 518-9544 or by email at GSEquityProspectusDelivery@guggenheimpartners.com. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Revolution Medicines, Inc. Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C), in addition to RAS companion inhibitors RMC-4630 and RMC-5552. Revolution Medicines Investors & Media Contacts: investors@revmed.com; media@revmed.comFraudsters Shift Tactics to Customers, Challenging Financial Institutions to InnovateNew Delhi, Nov 23 (IANS): After a video of former cricketer Navjot Singh Sidhu surfaced in which he described his wife's treatment for her breast cancer as "starving the cancer by not eating dairy products and sugar", Tata Memorial Hospital doctors on Saturday warned that diet alone is no cure for the disease, which requires a range of medical interventions. Oncologists at Tata Memorial Trust, in a post shared on X, said: "Diet alone is not a cure for cancer. While it plays a crucial role in supporting treatment and improving outcomes, cancer cure typically requires medical interventions like surgery, chemotherapy, and targeted therapies. Nutraceuticals and dietary changes can enhance the effectiveness of these treatments by targeting cancer pathways and improving the patient’s overall health. However, claims of curing cancer through diet alone lack scientific validation. Treatment plans should integrate diet as a complementary approach rather than a standalone solution, tailored to the individual’s cancer type and overall condition." Sidhu in a video, widely circulated on social media, had said that his wife starved the cancer by not eating dairy products and sugar and consumed haldi (turmeric) and neem which helped cure her "incurable" cancer. He said she ate her first meal of the day at 10 a.m. and the last meal of the day at 6.30 p.m. To this, the Tata Memorial doctors said: "These statements have no high-quality evidence to support them. While research is ongoing for some of these products, there is no clinical data currently to recommend their use as anti-cancer agents. We urge the public to not delay their treatment by following unproven remedies, but rather to consult a doctor, preferably a cancer specialist, if they have any symptoms of cancer. Cancer is curable if detected early and proven cancer treatments include surgery, radiation therapy and chemotherapy." At least 262 oncologists (present and past, from Tata Memorial Hospital) signed the statement. “Make this go viral. We have to keep fighting misinformation,” the Tata Memorial said.